The most common issues are mild injection-site reactions (redness, itching, swelling, tenderness, or bruising)
Semaglutide is a medication originally developed to treat type 2 diabetes, but recently, its gained popularity for its effectiveness in promoting weight loss
I.C.4.a.2 Assigning Diabetes Codes and Sequencing: E08 (DM due to underlying condition): Sequence the underlying condition FIRST (e.g., cystic fibrosis, Cushing syndrome), then E08.x
Typical values for HbA 1c measurement (using the previous standard Diabetes Control and Complications Trial, DCCT units of %) are shown in the Table below
In November 2023, federal officials approved the injection, sold under the brand name Zepbound , for adults with obesity or those who are overweight and also deal with weight-related medical issues such as hypertension, dyslipidemia or type 2 diabetes mellitus.
These formulations eliminate the need for injections entirely